Conformational memories and the endocannabinoid binding site at the cannabinoid CB1 receptor

被引:59
作者
Barnett-Norris, J
Hurst, DP
Lynch, DL
Guarnieri, F
Makriyannis, A
Reggio, PH
机构
[1] Kennesaw State Univ, Dept Chem & Biochem, Kennesaw, GA 30144 USA
[2] Sarnoff Corp, Princeton, NJ 08543 USA
[3] Univ Connecticut, Sch Pharm, Storrs, CT 06269 USA
关键词
D O I
10.1021/jm0200761
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Endocannabinoid stucture-activity relationships (SAR) indicate that the CB1 receptor recognizes ethanolamides whose fatty acid acyl chains have 20 or 22 carbons, with at least three homoallylic double bonds and saturation in at least the last five carbons of the acyl chain. To probe the molecular basis for these acyl chain requirements, the method of conformational memories (CM) was used to study the conformations available to an n-6 series of ethanolamide fatty acid acyl chain congeners: 22:4, n-6 (K-i = 34.4 +/- 13.2 nM); 20:4, n-6 (K-i = 39.2 +/- 5.7 nM); 20:3, n-6 (K-i = 53.4 +/- 5.5 nM); and 20:2, n-6 (K-i > 1500 nM). CM studies indicated that each analogue could form both extended and U/J-shaped families of conformers. However, for the low affinity 20:2, n-6 ethanolamide, the higher populated family was the extended conformer family, while for the other analogues in the series, the U/J-shaped family had the higher population. In addition, the 20:2, n-6 ethanolamide U-shaped family was not as tightly curved as were those of the other analogues studied. To quantitate this variation in curvature, the radius of curvature (in the C-3 to C-17 region) of each member of each U/J-shaped family was measured. The average radii of curvature (with their 95% confidence intervals) were found to be 5.8 Angstrom (5.3-6.2) for 20:2, n-6; 4.4 Angstrom (4.1-4.7) for 20:3, n-6; 4.0 Angstrom (3.7-4.2) for 20:4, n-6; and 4.0 Angstrom (3.6-4.5) for 22:4, n-6. These results suggest that higher CB1 affinity is associated with endocannabinoids that can form tightly curved structures. Endocannabinoid SAR also indicate that the CB1 receptor does not tolerate large endocannabinoid headgroups; however, it does recognize both polar and nonpolar moieties in the headgroup region. To identify a headgroup orientation that results in high CB1 affinity, a series of dimethyl anandamide analogues (R)N-(1-methyl-2-hydroxyethyl)-2-(R)-methyl-arachidonamide (K-i 7.42 +/- 0.86 nM), (R)-N-(1-methyl-2-hydroxyethyl)-2-(S)-methyl-arachidonamide (K-i 185 +/- 12 nM), (S)-N-(1-methyl-2hydroxyethyl)-2-(S)-methyl-arachidonamide (K-i = 389 +/- 72 nM), and (S)-N-(1-methyl-2hydroxyethyl)-2-(R)-methyl-arachidonamide (K-i = 233 +/- 69 nM) were then studied using CM and computer receptor docking studies in an active state (R*) model of CB1. These studies suggested that the high CB1 affinity of the RR stereoisomer is due to the ability of the headgroup to form an intramolecular hydrogen bond between the carboxamide oxygen and the headgroup hydroxyl that orients the C2 and C1' methyl groups to have hydrophobic interactions with valine 3.32(196), while the carboxamide oxygen forms a hydrogen bond with lysine 3.28(192) at CB1. In this position in the CB1 binding pocket, the acyl chain has hydrophobic and C-H...pi interactions with residues in the transmembrane helix (TMH) 2-3-7 region. Taken together, the studies reported here suggest that anandamide and its congeners adopt tightly curved U/J-shaped conformations at CB1 and suggest that the TMH 2-3-7 region is the endocannabinoid binding region at CB1.
引用
收藏
页码:3649 / 3659
页数:11
相关论文
共 50 条
  • [31] Recent advances in CB1 cannabinoid receptor antagonists
    Lange, JHM
    Kruse, CG
    [J]. CURRENT OPINION IN DRUG DISCOVERY & DEVELOPMENT, 2004, 7 (04) : 498 - 506
  • [32] Transmembrane Helical Domain of the Cannabinoid CB1 Receptor
    Shim, Joong-Youn
    [J]. BIOPHYSICAL JOURNAL, 2009, 96 (08) : 3251 - 3262
  • [33] Receptor dimerization of the μ-opioid and cannabinoid CB1 receptors
    Uezono, Y
    Matsumoto, M
    Kanaide, M
    Hojo, M
    Sumikawa, K
    Taniyama, K
    [J]. JOURNAL OF PHARMACOLOGICAL SCIENCES, 2005, 97 : 134P - 134P
  • [34] Changes in the density of the cannabinoid CB1 receptor in schizophrenia
    Sundram, S
    Bradbury, R
    Scarr, E
    Copolov, DL
    Dean, B
    [J]. SCHIZOPHRENIA RESEARCH, 2001, 49 (1-2) : 85 - 85
  • [35] Pharmacophoric mapping of the CB1 cannabinoid receptor.
    Tong, WD
    Collantes, ER
    Shim, JY
    Welsh, WJ
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1997, 213 : 12 - COMP
  • [36] Pentacycle derivatives as cannabinoid CB1 receptor ligands
    Lee, Suk Ho
    Seo, Hee Jeong
    Kim, Min Ju
    Kang, Suk Youn
    Lee, Sung-Han
    Ahn, Kwangwoo
    Lee, MinWoo
    Han, Ho-Kyun
    Kim, Jeongmin
    Lee, Jinhwa
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2009, 19 (23) : 6632 - 6636
  • [37] CB1 Cannabinoid Receptor Signaling and Biased Signaling
    Leo, Luciana M.
    Abood, Mary E.
    [J]. MOLECULES, 2021, 26 (17):
  • [38] Cannabinoid CB1 receptor and gastric acid secretion
    Borrelli, Francesca
    [J]. DIGESTIVE DISEASES AND SCIENCES, 2007, 52 (11) : 3102 - 3103
  • [39] Substituted pyrimidines as cannabinoid CB1 receptor ligands
    Kim, Min Ju
    Kim, Jong Yup
    Seo, Hee Jeong
    Lee, Junwon
    Lee, Sung-Han
    Kim, Mi-Soon
    Kang, Jahyo
    Kim, Jeongmin
    Lee, Jinhwa
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2009, 19 (16) : 4692 - 4697
  • [40] Crystal Structure of the Human Cannabinoid Receptor CB1
    Hua, Tian
    Vemuri, Kiran
    Pu, Mengchen
    Qu, Lu
    Han, Gye Won
    Wu, Yiran
    Zhao, Suwen
    Shui, Wenqing
    Li, Shanshan
    Korde, Anisha
    Laprairie, Robert B.
    Stahl, Edward L.
    Ho, Jo-Hao
    Zvonok, Nikolai
    Zhou, Han
    Kufareva, Irina
    Wu, Beili
    Zhao, Qiang
    Hanson, Michael A.
    Bohn, Laura M.
    Makriyannis, Alexandros
    Stevens, Raymond C.
    Liu, Zhi-Jie
    [J]. CELL, 2016, 167 (03) : 750 - +